...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Vitamin b(6) treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
【24h】

Vitamin b(6) treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.

机译：维生素b（6）在急性精神抑制药引起的静坐症中的治疗：一项随机，双盲，安慰剂对照的研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Treatment strategies for acute neuroleptic-induced akathisia (NIA) contain anticholinergic (antimuscarinic) agents, dopamine agonists, gamma-aminobutyric acid (GABA)-ergic agents, beta-blockers, benzodiazepines, and serotonin antagonists. Nevertheless, many patients who suffer from acute akathisia fail to respond to treatment. In earlier studies, vitamin B(6) was found to be effective in the treatment of neuroleptic-induced movement disorders. The purpose of this study was to evaluate the efficacy of vitamin B(6) in the treatment of acute NIA. This is the first report of B(6) as a treatment for NIA. METHOD: This study was conducted in 2 mental health centers from February 2003 to November 2003. Twenty schizophrenia and schizoaffective inpatients with a DSM-IV diagnosis of NIA were randomly divided to receive vitamin B(6) 600 mg/day b.i.d. (N = 10) or placebo (N = 10) twice a day for 5 days in a double-blind design. The Barnes Akathisia Scale (BAS), the Brief Psychiatric Rating Scale (BPRS),and the Clinical Global Impressions scale (CGI) were used to assess the severity of NIA and psychotic symptoms. The BAS assessment was made at baseline and every day during the study. The BPRS and CGI were completed at baseline and at the end of the study. RESULTS: The vitamin B(6)-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS. The objective subscale did not demonstrate significant positive results (p = .079), but there was a trend of symptom amelioration in the vitamin B(6) group. A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B(6) group (80%), and in only 3 patients in the placebo group (30%) (p = .037). CONCLUSION: Our preliminary results indicate that high doses of vitamin B(6) may be useful additions to the available treatments for NIA, perhaps due to its combined effects on various neurotransmitter systems.
机译：背景：急性神经安定性静坐症（NIA）的治疗策略包括抗胆碱能（抗毒蕈碱）剂，多巴胺激动剂，γ-氨基丁酸（GABA）激动剂，β受体阻滞剂，苯二氮卓类和5-羟色胺拮抗剂。然而，许多患有急性静坐不稳的患者对治疗没有反应。在较早的研究中，发现维生素B（6）可有效治疗精神抑制药引起的运动障碍。这项研究的目的是评估维生素B（6）在治疗急性NIA中的功效。这是B（6）作为NIA治疗的第一份报告。方法：本研究于2003年2月至2003年11月在2个精神卫生中心进行。将20例精神分裂症和精神分裂症患者以DSM-IV诊断为NIA，随机分为两组，分别接受每日600 mg / d的维生素B（6）。 （N = 10）或安慰剂（N = 10），每天两次，共5天，采用双盲设计。使用Barnes Akathisia量表（BAS），简要精神病评定量表（BPRS）和临床总体印象量表（CGI）评估NIA和精神病性症状的严重程度。在研究期间和基线进行BAS评估。 BPRS和CGI在基线和研究结束时完成。结果：与安慰剂组相比，接受维生素B（6）治疗的患者在主观不安感（p = .0004），主观困扰（p = .01）和整体性（p = .004）BAS的子量表。客观量表未显示出明显的阳性结果（p = .079），但维生素B（6）组有症状改善的趋势。维生素B（6）组中的8例患者（80％）和安慰剂组中只有3例（30％）的BAS全球子评分至少降低了2分（p = .037）。结论：我们的初步结果表明，高剂量的维生素B（6）可能是对NIA可用治疗的有用补充，也许是由于其对各种神经递质系统的综合作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号